Morgan Stanley Initiates Coverage On Acelyrin with Overweight Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit initiates coverage on Acelyrin (NASDAQ:SLRN) with an Overweight rating and a price target of $29.
May 30, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley initiates coverage on Acelyrin with an Overweight rating and a price target of $29.
Morgan Stanley's initiation of coverage on Acelyrin with an Overweight rating and a price target of $29 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100